SuperworthFulcrum Therapeutics market cap FULC
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Oct 23, 2026
- $280.8M
- Highest close in our data
- $1B
- Sep 2021
Fulcrum Therapeutics is worth $280.8M at the close on Oct 23, 2026, at $3.68 a share.
That is down 44% over the last year and down 61% over five years.
Its highest close in our data was $1B in Sep 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $280.8M | $229.9M | $595.3M | −55% |
| 2025 | $626.7M | $135.5M | $703.5M | +143% |
| 2024 | $258.4M | $162.4M | $703.6M | −38% |
| 2023 | $417.3M | $147M | $713.1M | +10% |
| 2022 | $378.9M | $187.5M | $964.7M | −47% |
| 2021 | $717.3M | $238.9M | $1B | +123% |
| 2020 | $321.6M | $198.2M | $513.5M | −19% |
| 2019 | $395.6M | $106.7M | $395.6M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Fulcrum Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| FULCFulcrum Therapeutics | $280.8M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| LFVNLifevantage | $73.4M |
| Peer median | $577.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Fulcrum Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.